Deletion of C7L and K1L Genes Leads to Significantly Decreased Virulence of Recombinant Vaccinia Virus TianTan

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Liu, Zheng ^a   Wang, Shuhui ^a   Zhang, Qicheng ^a,b   Tian, Meijuan ^c   Hou, Jue ^a   Wang, Rongmin ^d   Liu, Chang ^a   Ji, Xu ^a   Liu, Ying ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NANKAI UNIVERSITY   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Clinical Laboratory   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CEF CELL; CELL STRAIN; CELL STRAIN BHK; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; ERYTHEMA; FEMALE; GENE DELETION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; RABBIT; VACCINIA; VACCINIA VIRUS; VERO CELL; VIRUS GENE; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; FEMALE; GENE DELETION; GENES, VIRAL; GENETIC VECTORS; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RABBITS; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS; VACCINIA VIRUS;

EID: 84879707628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068115     Document Type: Article

References (42)

1. Moss B, (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93: 11341-11348. doi:10.1073/pnas.93.21.11341. PubMed: 8876137.
2. Paoletti E, (1996) Applications of poxvirus vectors to vaccination: an update. Proc Natl Acad Sci U S A 93: 11349-11353. doi:10.1073/pnas.93.21.11349. PubMed: 8876138.
3. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, et al. (2011) Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. J Infect Dis 203: 969-975. doi:10.1093/infdis/jiq152. PubMed: 21402548.
4. Karasavvas N, Billings E, Rao M, Williams C, Zolla PS, et al. (2012) The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Res Hum Retrovir 28: 1444-1457. doi:10.1089/aid.2012.0103. PubMed: 23035746.
5. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, et al. (2012) Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 478.
6. De Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. doi:10.4049/jimmunol.1102756. PubMed: 22529301.
7. Liu Y, Duan DL, Peng H, Tang HL, Liu S, et al. (2004) Immunogenicity analysis of HIV vaccine based on replicating vaccinia virus Tiantan vector. Zhong Hua Shi Yan He Lin Chuang Bing Xue Zhi 18: 281-283.
8. Wang WL, Huang BY, Deng Y, Wang XP, Tan WJ, et al. (2007) Expression of Influenza A3 Virus(H3N2)M2 Gene inVaccinia Virus Tiant Strain. Chin J of Virology 24: 377-383.
9. Li P, Zhu JH, Yan JX, Guo F, Hu QL, et al. (2000) Co-expressing of rabies virus glycoprotein and nucleoprotein in the non-replicating vaccinia viurs TianTan strain Chin J Microbiol Immunol 20: 481-484.
10. Zhang Y, Yang JY, Bao R, Chen YQ, Zhou DH, (2011) Unpolarized release of vaccinia virus and HIV antigen by colchicinet reatment enhances intranasal HIV antigen expression and mucosal humoral responses. PLOS ONE 6: e24296. doi:10.1371/journal.pone.0024296. PubMed: 21935396.
11. Huang XX, Lu B, Yu WB, Fang Q, Liu L, (2009) A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLOS ONE 4: e4180. doi:10.1371/journal.pone.0004180. PubMed: 19159014.
12. Tang X, Chen Z, (2010) The development of an AIDS mucosal vaccine. Viruses 2: 283-297. doi:10.3390/v2010283. PubMed: 21994611.
13. Dai K, Liu Y, Liu M, Xu J, Huang W, et al. (2008) Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26: 5062-5071. doi:10.1016/j.vaccine.2008.06.011. PubMed: 18573290.
14. Fang Q, Yang L, Zhu WJ, Liu L, Wang HB, (2005) Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 335: 242-251. doi:10.1016/j.virol.2005.02.014. PubMed: 15840523.
15. Zhu WJ, Fang Q, Zhuang K, Wang HB, Yu WB, (2007) The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods 144: 17-26. doi:10.1016/j.jviromet.2007.03.012. PubMed: 17459491.
16. Gherardi MM, Pérez-Jiménez E, Nájera JL, Esteban M, (2004) Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modifi{ligature}ed vaccinia virus Ankara boost immunization schedule. J Immunol 172: 6209-6220. PubMed: 15128809.
17. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, et al. (2004) Public health. A sound rationale needed for phaseIII HIV-1 vaccine trials. Science 303: 316. doi:10.1126/science.1094620. PubMed: 14726576.
18. Elena GC, Perdiguero B, Garcia-Arriaza J, Esteban M, (2012) Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8(9):1192-1207.
19. Harari A, Rozot V, Cavassini M, Enders FB, Vigano S, et al. (2012) NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol 42: 3038-3048. doi:10.1002/eji.201242696. PubMed: 22930439.
20. Moss B, (2007) Poxviridae: the viruses and their replication. Fields Virology 2: 2905-2946.
21. Perkus ME, Goebel SJ, Davis Stephen W, Johnson GP, Limbach K, et al. (1990) Vaccinia Virus Host Range Genes Virology 179: 276-286.
22. Gerd S, Anna RE, Riardo R, Moss B, (1994) Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol 68: 4109-4116. PubMed: 8207789.
23. Li YC, Meng XZ, Yan X, Deng JP, (2010) Structure function studies of vaccinia virus host range protein K1 reveal a novel functional surface for ankyrin repeat proteins. J Vriol 84: 3331-3338. doi:10.1128/JVI.02332-09.
24. Drillien R, Koehren F, Kirn A, (1981) Host range deletion mutant of vaccinia virus defective in human cells. Virology 111: 488-499. doi:10.1016/0042-6822(81)90351-2. PubMed: 6264670.
25. Gillard S, Spehner D, Drillien R, Kirn A, (1986) Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci U S A 83: 5573-5577. doi:10.1073/pnas.83.15.5573. PubMed: 3461450.
26. Meng X, Chao J, Xiang Y, (2008) Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology 372: 372-383. doi:10.1016/j.virol.2007.10.023. PubMed: 18054061.
27. Perrakis A, Morris R, Lamzin VS, (1999) Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6: 458-463. doi:10.1038/8263. PubMed: 10331874.
28. Tian MJ, Liu Y, Ma Y, Liu Z, Ling DW, et al. (2010) Pathogenicity and immunogenicity of recombinant HIV Tiantan vaccinia virus expressing IL-12. Chian Tropical Medicine 10: 653-655.
29. Kan SF, Wang YH, Sun LL, Jia P, Qi YX, et al. (2012) Attenuation of Vaccinia Tian Tan Strain by Removal of Viral TC7L-TK2L and TA35R Genes. PLOS ONE 7: e31979. doi:10.1371/journal.pone.0031979. PubMed: 22363781.
30. Patricia LE, Jeffrey LA, Linda SW, (2007) Recombinant Modified Vaccinia Virus Ankara Provides Durable Protection Against Disease Caused by an Immunodeficiency Virus as well as Long Term Immunity to an Orthopoxvirus in a Non-Human Primate. Virology 366: 84-97. doi:10.1016/j.virol.2007.02.041. PubMed: 17499326.
31. Weyer J, Kuzmin IV, Rupprecht CE, Nel LH, (2008) Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes. Epidemiol Infect 136: 670-678. PubMed: 17588277.
32. Ranasinghe C, Eyers F, Stambas J, Boyle DB, (2011) A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 29: 3008-3020. doi:10.1016/j.vaccine.2011.01.106. PubMed: 21352941.
33. Rodri{dotless}, guez D, Gloria GA, Juan RR (2012) Vaccine Efficacy against Malaria by the Combination of Porcine Parvovirus-Like Particles and Vaccinia Virus Vectors Expressing CS of Plasmodium. PLOS ONE 7: e34445. doi:10.1371/journal.pone.0034445. PubMed: 22529915.
34. Werden SJ, Rahman MM, McFadden G, (2008) Poxvirus host range genes. Adv Virus Res 71: 135-171. doi:10.1016/S0065-3527(08)00003-1. PubMed: 18585528.
35. The Committee for Biological Product Standardization in China (1979) Requirements for the Manufacture of Biological Products in China. Beijing, P.R.China: Chemical Industry Publishing House of China.
36. Ramsey-Ewing AL, Moss B, (1996) Complementation of a vaccinia virus host-range K1L gene deletion by the nonhomologous CP77 gene. Virology 222(1):: 75-86. doi:10.1006/viro.1996.0399. PubMed: 8806489.
37. Chung CS, Vasilevskaya IA, Wang SC, Bair CH, Chang W, (1997) Apoptosis and host restriction of vaccinia virus in RK13 cells. Virus Res 52: 121-132. doi:10.1016/S0168-1702(97)00111-1. PubMed: 9495528.
38. Oguiura N, Spehner D, Drillien R, (1993) Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J Gen Virol 74: 1409-1413. doi:10.1099/0022-1317-74-7-1409. PubMed: 8336123.
39. Kristen LW, Samir P, Yan X, Joanna LS, (2009) The effect of the vaccinia K1 protein on the PKR-eIF2α pathway in RK13 and HeLa cells. Virology 394: 73-81. doi:10.1016/j.virol.2009.08.020. PubMed: 19744687.
40. Simone B, Karin MS, Joachim Z, Georg G, (2010) Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphory lation of eukaryotic translation initiation factor 2α. J Gen Virol 91: 470-482. doi:10.1099/vir.0.015347-0. PubMed: 19846675.
41. Paoletti E, Tartaglia J, Taylor J, (1994) Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 82: 65-69. PubMed: 7958484.
42. Drexler I, Chamberlain RS, Sutter G, (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506-512. doi:10.1016/j.copbio.2004.09.001. PubMed: 15560976.